NASDAQ · RPTX
Repare Therapeutics Inc.
$2.65$0.00 (0.0%)
Repare Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.38% below the high.
Loading market information…
NASDAQ · RLMD · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Relmada Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Relmada Therapeutics, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.14. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Relmada Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:15 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Mar 27, 2025 |
| -$0.62+11.43% vs estimate |
| $0.00 |
| Q3 2024 | Nov 7, 2024 | -$0.72-10.77% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $12.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$2.65$0.00 (0.0%)
Repare Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.38% below the high.
$7.80-$0.19 (-2.32%)
Immunic, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.28% below the high.
$0.43+$0.02 (+4.66%)
Vaxart, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.17% below the high.
$1.35-$0.06 (-4.26%)
Cibus, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.79% below the high.
$1.76-$0.03 (-1.68%)
Acrivon Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 50.56% below the high.
$1.35-$0.03 (-2.17%)
PMV Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.32% below the high.
$2.00+$0.04 (+2.04%)
Fortress Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.85% below the high.
$1.17-$0.06 (-4.88%)
Lite Strategy, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.23% below the high.
